We welcome the critical review by Montassier and Freund on our article on the rationale and methods of the "MEDITA" study \[[@CR1]\]. Below, we provide point-by-point answers to all comments.

Methoxyflurane is currently being introduced in Europe, and its use is supported by robust data in the literature (including the STOP! study \[[@CR2]\]) and by extensive experience in clinical practice, particularly in Australia. Although such data are adequate to support the introduction into clinical practice in Europe, further head-to-head studies vs. the best currently used therapeutic options, in terms of effectiveness and rapidity of onset, are needed. These data will help to identify methoxyflurane's place in therapy, which today is a promising option with potential advantages compared with the drugs on the market. There are now emerging data in Europe: the "InMediate" study \[[@CR3]\], which randomised 310 patients with trauma pain to methoxyflurane or standard of care (SoC) analgesia, has recently been completed in Spain. Preliminary results indicate that methoxyflurane significantly (*p* \< 0.0001) reduced pain severity compared with SoC up to 20 min after the start of treatment \[[@CR4]\]. Another ongoing study, "PenASAP", will randomise 360 patients with trauma pain in a double-blind fashion to Penthrox or placebo, administered in addition to SoC \[[@CR5]\]. These studies, together with the MEDITA study, which is the subject of this letter \[[@CR1]\], all conducted with high methodological and qualitative standards, aim to resolve the uncertainties that currently persist.

Oral analgesia was not used to treat patients with moderate pain (NRS 4--6) in the MEDITA study since intravenous (IV) therapy is the common clinical practice in Italy where the study was conducted, although it should be underlined that there is wide heterogeneity in the therapeutic approach and oligoanalgesia still represents a widespread issue. The use of IV formulations is consistent with Italian Intersociety Recommendations on pain management in the emergency setting \[[@CR6]\]. Likewise, in the Spanish InMediate study, oral agents were administered to only 10.7% of patients in the SoC group, although it should be noted that the majority of patients (76.5%) had severe pain (NRS ≥ 7). Moreover, we think that in the context of a clinical study, to evaluate the net efficacy of the molecule, it is more appropriate to use an IV formulation to make the comparison more homogeneous and to obtain head-to-head data vs. the most effective therapeutic option. A comparison vs. oral drugs would have given an obvious result because of the latency in the onset of action. A pharmacoeconomic analysis will be conducted separately at the end of the study.

The primary pain intensity end point in the "MEDITA" study is assessed over the first 10 min because of the rapid action of the drug and represents the most challenging comparison for methoxyflurane. By definition, IV medicinal products are immediately ready to act. This also correlates with the indication of methoxyflurane: emergency relief of moderate-to-severe pain in conscious adult patients with trauma and associated pain and the unmet need of receiving an easy-to-use, rapid-acting and effective first-line analgesic treatment for trauma-related pain. Methoxyflurane is already known to be effective at 30 min, so the 10-min end point in the MEDITA trial provides additional information about its efficacy profile. Long duration of action is not the goal of methoxyflurane treatment. In any case, intermittent administration produces a longer analgesic effect, and if required there is the option to administer a second 3-ml dose in clinical practice. While the Penthrox inhaler indeed requires responsible disposal \[[@CR7]\], other analgesics also have challenges in terms of consumables that are single use and non-recyclable (e.g. syringes, flasks, cannulas, needles, etc.).

Finally, Mundipharma strongly encourages and supports independent research as far as possible, and we agree that third parties have an important role to play in future investigations of methoxyflurane.
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